The study found that two immune signaling proteins, CXCL10 and IFN-gamma, appear to play a central role. Researchers observed that certain immune cells exposed to the vaccine produced these inflammatory signals, which then appeared to trigger immune activity that could affect heart tissue. Their results in lab experiments, mice, and heart-like tissue models suggested that this inflammatory chain may help explain the rare cases of heart inflammation seen after vaccination.
At the same time, the overall risk remains low, and researchers stressed the broader context. Vaccine-associated myocarditis is uncommon, while COVID-19 infection itself has been reported to carry a higher risk of causing myocarditis along with other serious complications. The study also found that blocking the specific inflammatory signals reduced heart-related damage in experiments without fully removing the broader immune response.
The team also explored genistein, a compound found in soy, and found that it reduced harmful effects in their experimental models. While that does not mean it is an immediate treatment, it suggests there may be ways in the future to lower the risk while preserving vaccine benefits. Overall, the findings provide a clearer explanation for a rare side effect and point toward possible strategies to make mRNA-based treatments even safer.
